IP Library › Granted Patent US 10,131,891
Granted Patent B2
US 10,131,891 · App. 15/541,123 · Granted Nov 20, 2018

Method of using insulin for controlling glycosylation of recombinant glycoprotein

Inventors: Kyu Yong Kim (Daejeon, KR); Soo Hyun Ryu (Daejeon, KR); Sam Sook Seol (Daejeon, KR); Sun Young Kim (Daejeon, KR)
Assignee: LG CHEM, LTD.
C12N9/24A61K38/1741C07K14/62C07K14/705C07K16/00C07K19/00C12N15/52C12N15/74C12P19/18C12P21/00C07K2317/14C07K2317/21C07K2317/41
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,131,891
App. No.
15/541,123
Granted
Nov 20, 2018
Kind
B2
Abstract

The present invention relates to a method for controlling a glycosylation pattern of a recombinant glycoprotein, comprising culturing a cell comprising polynucleotide encoding a recombinant glycoprotein in a culture medium comprising insulin.

Claims (17)

1. A method for controlling a glycosylation pattern of a recombinant glycoprotein, comprising culturing a microorganism comprising a polynucleotide encoding the recombinant glycoprotein in a culture medium comprising insulin, wherein said insulin is in an amount sufficient to reduce any N-glycans and/or O-glycans on said recombinant glycoprotein.

2. The method of claim 1 , wherein the recombinant glycoprotein is an immunoglobulin fusion protein.

3. The method of claim 1 , wherein the recombinant glycoprotein is a Tumor Necrosis Factor Receptor (TNFR)-Fc fusion protein.

4. The method of claim 1 , wherein a concentration of the insulin is 0.0001 mg/L to 1 g/L relative to the total volume of the culture medium.

5. The method of claim 1 , wherein the insulin controls N-linked glycosylation and O-linked glycosylation.

6. The method of claim 1 , wherein the insulin reduces any N-glycan content of the recombinant glycoprotein.

7. The method of claim 1 , wherein the insulin reduces any O-glycan content of the recombinant glycoprotein.

8. The method of claim 1 , wherein the culturing is a perfusion culturing method.

9. A method for controlling a glycosylation pattern of a recombinant glycoprotein, comprising:

(a) culturing a microorganism comprising a polynucleotide encoding a recombinant glycoprotein in a culture medium to grow the microorganism; and

(b) adding insulin to the culture medium and culturing the same to produce a glycoprotein, wherein said insulin is added in an amount sufficient to reduce any N-glycans and/or O-glycans on said recombinant glycoprotein.

10. The method of claim 9 , wherein said insulin is added at different concentrations to produce a target glycosylation pattern.

11. The method of claim 10 , wherein the insulin is added in an amount sufficient to reduce the amount of any N-glycan or O-glycan on the recombinant glycoprotein.

12. The method of claim 9 , wherein the recombinant glycoprotein is an immunoglobulin fusion protein.

13. The method of claim 9 , wherein the recombinant glycoprotein is a TNFR-Fc fusion protein.

14. The method of claim 9 , wherein a concentration of the insulin is 0.0001 mg/L to 1 g/L relative to the total volume of the culture medium.

15. The method of claim 9 , wherein the culturing is a perfusion culturing method.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2017
From: KIM, KYU YONG; RYU, SOO HYUN; SEOL, SAM SOOK; KIM, SUN YOUNG
To: LG CHEM, LTD.
Reel/Frame 043629/0636 →
Priority Claims (1)
KR 10-2014-0195976 · Dec 31, 2014 · national
Continuity (1)
Related Publication 20170342392A1 · Nov 30, 2017